Gouws Capital LLC Sells 122 Shares of Eli Lilly and Company (NYSE:LLY)

Gouws Capital LLC decreased its stake in shares of Eli Lilly and Company (NYSE:LLY) by 0.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 17,505 shares of the company’s stock after selling 122 shares during the period. Eli Lilly and Company accounts for 9.3% of Gouws Capital LLC’s portfolio, making the stock its 2nd largest position. Gouws Capital LLC’s holdings in Eli Lilly and Company were worth $13,514,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of LLY. Intact Investment Management Inc. lifted its stake in shares of Eli Lilly and Company by 27.7% in the 3rd quarter. Intact Investment Management Inc. now owns 2,580 shares of the company’s stock valued at $2,286,000 after purchasing an additional 560 shares in the last quarter. Quintet Private Bank Europe S.A. raised its holdings in Eli Lilly and Company by 6.9% in the third quarter. Quintet Private Bank Europe S.A. now owns 4,369 shares of the company’s stock valued at $3,871,000 after buying an additional 281 shares during the period. Hazlett Burt & Watson Inc. raised its holdings in Eli Lilly and Company by 8.1% in the third quarter. Hazlett Burt & Watson Inc. now owns 1,458 shares of the company’s stock valued at $1,293,000 after buying an additional 109 shares during the period. Moloney Securities Asset Management LLC lifted its position in Eli Lilly and Company by 22.0% during the third quarter. Moloney Securities Asset Management LLC now owns 6,540 shares of the company’s stock valued at $5,794,000 after buying an additional 1,178 shares in the last quarter. Finally, FSM Wealth Advisors LLC grew its stake in Eli Lilly and Company by 12.9% during the third quarter. FSM Wealth Advisors LLC now owns 1,406 shares of the company’s stock worth $1,246,000 after buying an additional 161 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on LLY shares. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a research report on Friday, January 17th. Truist Financial upped their target price on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Bank of America reiterated a “buy” rating and set a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, Wells Fargo & Company reduced their price target on Eli Lilly and Company from $1,000.00 to $970.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Three analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,000.28.

Eli Lilly and Company Trading Down 2.0 %

NYSE LLY opened at $910.92 on Wednesday. The company has a market capitalization of $863.70 billion, a price-to-earnings ratio of 77.79, a price-to-earnings-growth ratio of 1.40 and a beta of 0.42. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53. The company’s fifty day moving average price is $819.86 and its two-hundred day moving average price is $848.03.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be given a $1.50 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.66%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 51.24%.

Eli Lilly and Company declared that its board has initiated a share buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in outstanding shares. This repurchase authorization allows the company to repurchase up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.